

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
33677-00000SERIAL NO.:  
09/382,837

## INFORMATION DISCLOSURE STATEMENT

APPLICANT:  
Gary BORODICFILING DATE:  
August 25, 1999GROUP ART UNIT:  
1644

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

182	51	/	Nakamura, S., et al., Sporulation and C2 toxin production by Clostridium botulinum type C strains producing no C1 toxin, <i>Microbial Immunol</i> 1978; 22(10):591-6.
	52	/	Ohishi, I., et al., Histopathological effect of botulinum C2 toxin on mouse intestines, <i>Infect Immun</i> 1/84; 43(1): 54-8.
	53		<del>Definitive radiation therapy for the treatment of the ocular adnexa, <i>Int J Radiat Oncol Biol Phys</i> 3/15/96; 34(5):1189-90.</del>
	54	/	Pearce, L., et al., Pharmacologic characterization of botulinum toxin for basic science and medicine, <i>Toxicon</i> 9/97; 35(9):1373-412.
	55	/	Pearce, L., et al., Botulinum toxin: death versus localized denervation, <i>J R Soc Med</i> 4/95; 88(4):239-40.
	56	/	Pearce, L., et al., The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin, <i>Toxicon</i> 2/95; 33(2):217-27.
	57	/	Pearce, L., et al., Measurement of botulinum toxin activity: evaluation of the lethality assay, <i>Toxicol Appl Pharmacol</i> 9/94; 128(1):69-77.
	58	/	Pearce, L., et al., Botulinum toxin potency: a mystery resolved by the median paralysis, <i>J R Soc Med</i> 9/94; 87(9):571-2.
	59	/	Ritter, A., et al., Regulation of myelinated nociceptor function by nerve growth factor in neonatal and adult rats, <i>Br Res Bul</i> 1993; 30:245-49.
	60	/	Sanico, A., et al., Nerve growth factor expression and release in allergic inflammatory disease of the upper airways, <i>Am J Respir Crit Care Med</i> 2000; 161:1631-5.
	61	/	Simpson, L., A comparison of the pharmacological properties of Clostridium botulinum type C1 and C2 toxins, <i>J Pharmacol Exp Ther</i> 12/82; 223(3):695-701.
	62	/	Simpson, L., Molecular basis for the pharmacological actions of Clostridium botulinum type C2 toxin, <i>J Pharmacol Exp Ther</i> 9/84; 230(3):665-9.
	63		Tarsy, D., et al., Myasthenia gravis after botulinum toxin A for Meige syndrome, <i>Mov Disord</i> 7/00; 15(4):736-8. <span style="float: right;">Wydase</span>
	64	/	Troll, G., et al., Diplopia after cataract surgery using 4% lidocaine in the absence of <del>Wydase</del> <i>J Clin Anesth</i> 11/99; 11(7):615-6. <span style="float: right;">^</span>
	65		<del>Wex, C., et al., Effects of electroporation on the depolymerization of actin on degranulation of eosinophil granulocytes, <i>Naunyn-Schmiedeberg Arch Pharmacol</i> 1997; 355:319-27.</del>
182	66	/	Woolf, C., et al., Peripheral cell types contributing to the hyperalgesic action of nerve growth factor in inflammation, <i>J Neurosci</i> 4/15/96; 16(8): 2716-23.